MicroRNA-33b is a potential non-invasive biomarker for response to atorvastatin treatment in chilean subjects with hypercholesterolemia: a pilot study
Author
dc.contributor.author
Ubilla, Carmen Gloria
Author
dc.contributor.author
Prado, Yalena
Author
dc.contributor.author
Angulo, Jeremy
Author
dc.contributor.author
Obreque, Ignacio
Author
dc.contributor.author
Páez, Isis
Author
dc.contributor.author
Saavedra, Nicolás
Author
dc.contributor.author
Saavedra, Kathleen
Author
dc.contributor.author
Zambrano Coloma, Tomás Andrés
Author
dc.contributor.author
Salazar, Luis A.
Admission date
dc.date.accessioned
2021-11-15T19:30:34Z
Available date
dc.date.available
2021-11-15T19:30:34Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Frontiers in Pharmacology May 2021 | Volume 12 | Article 674252
es_ES
Identifier
dc.identifier.other
10.3389/fphar.2021.674252
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/182697
Abstract
dc.description.abstract
Evidence accumulated so far indicates that circulating levels of microRNAs (miRNAs) are associated with several pathologies. Therefore, differential expression of extracellular miRNAs exhibits promising potential for screening and diagnosis purposes. We evaluated plasma miRNAs in response to the lipid-lowering drug atorvastatin in patients with hypercholesterolemia (HC) and controls. Methods: We selected miRNAs based on previous data reported by our group and also by employing bioinformatics tools to identify 10 miRNAs related to cholesterol metabolism and statin response genes. Following miRNA identification, we determined plasma levels of miRNA-17-5p, miRNA-30c-5p, miRNA-24-3p, miRNA-33a-5p, miRNA-33b-5p, miRNA-29a-3p, miRNA-29b-3p, miRNA-454-3p, miRNA-590-3p and miRNA-27a-3p in 20 HC patients before and after 1 month of 20 mg/day atorvastatin treatment, evaluating the same miRNA set in a group of 20 healthy subjects, and employing qRT-PCR to determine differential miRNAs expression. Results: HC individuals showed significant overexpression of miRNA-30c-5p and miRNA-29b-3p vs. NL (p = 0.0008 and p = 0.0001, respectively). Once cholesterol-lowering treatment was concluded, HC individuals showed a substantial increase of three extracellular miRNAs (miRNA-24-3p, miRNA-590, and miRNA-33b-5p), the latter elevated more than 37-fold (p = 0.0082). Conclusion: Data suggest that circulating miRNA-30c-5p and miRNA-29b-3p are associated with hypercholesterolemia. Also, atorvastatin induces a strong elevation of miRNA-33b-5p levels in HC individuals, which could indicate an important function that this miRNA may exert upon atorvastatin therapy. Additional studies are needed to clarify the role of this particular miRNA in statin treatment.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT
1171765
Direccion de Investigacion of the Universidad de La Frontera
DI19-2018
ANID-Chile Doctoral Scholarship
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
Frontiers Media
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States